Kara N Maxwell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1529317/publications.pdf

Version: 2024-02-01

62 3,532 24 52 papers citations h-index g-index

66 66 66 6174 all docs docs citations times ranked citing authors

#	Article	lF	Citations
1	Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7100-7105.	3.3	548
2	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
3	Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2069-2074.	3.3	359
4	Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research, 2003, 44, 2109-2119.	2.0	325
5	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	5.8	212
6	The spd-2 gene is required for polarization of the anteroposterior axis and formation of the sperm asters in the Caenorhabditis elegans zygote. Developmental Biology, 2000, 222, 55-70.	0.9	149
7	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine, 2015, 17, 630-638.	1.1	128
8	The incidence of both serious and minor complications in young women undergoing oocyte donation. Fertility and Sterility, 2008, 90, 2165-2171.	0.5	114
9	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
10	Population Frequency of Germline <i>BRCA1/2</i> Mutations. Journal of Clinical Oncology, 2016, 34, 4183-4185.	0.8	107
11	Differential Gene Regulation of StarD4 and StarD5 Cholesterol Transfer Proteins. Journal of Biological Chemistry, 2005, 280, 19410-19418.	1.6	103
12	Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Current Opinion in Lipidology, 2005, 16, 167-172.	1.2	78
13	Cancer treatment according to BRCA1 and BRCA2 mutations. Nature Reviews Clinical Oncology, 2012, 9, 520-528.	12.5	69
14	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003302.	3.9	63
15	Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. Journal of Clinical Investigation, 2020, 130, 4252-4265.	3.9	61
16	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clinical Cancer Research, 2019, 25, 4363-4374.	3.2	60
17	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genetics in Medicine, 2016, 18, 25-33.	1.1	56
18	Analysis of the Li-Fraumeni Spectrum Based on an International Germline <i>TP53</i> Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55

#	Article	IF	CITATIONS
19	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	7.7	41
20	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
21	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
22	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Research and Treatment, 2020, 181, 181-188.	1.1	36
23	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
24	Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer. JAMA Oncology, 2020, 6, 921.	3.4	26
25	Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	1.4	26
26	Research participants' experiences with return of genetic research results and preferences for webâ€based alternatives. Molecular Genetics & Enomic Medicine, 2019, 7, e898.	0.6	24
27	Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 164, 627-638.	1.1	21
28	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precision Oncology, 2019, 3, 1-11.	1.5	20
29	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	0.6	19
30	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> Along Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
31	Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution. Clinical and Translational Science, 2018, 11, 85-92.	1.5	17
32	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology, 2022, 81, 559-567.	0.9	17
33	Suggested application of HER2+ breast tumor phenotype for germline <i>TP53</i> variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562.	1.1	16
34	The distinct impacts of race and genetic ancestry on health. Nature Medicine, 2022, 28, 890-893.	15.2	16
35	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precision Oncology, 2018, 2, 1-24.	1.5	15
36	Antibodies to PCSK9. Circulation Research, 2012, 111, 274-277.	2.0	14

3

#	Article	IF	Citations
37	Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank. Genetics in Medicine, 2022, 24, 601-609.	1.1	13
38	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
39	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. American Journal of Gastroenterology, 2020, 115, 2095-2097.	0.2	9
40	Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 740.	1.2	9
41	Familial Breast Cancer Risk. Current Breast Cancer Reports, 2013, 5, 170-182.	0.5	8
42	Allele-specific copy number estimation by whole exome sequencing. Annals of Applied Statistics, 2017, 11, 1169-1192.	0.5	8
43	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Briefings in Bioinformatics, 2016, 17, 672-677.	3.2	6
44	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget, 2016, 7, 48577-48585.	0.8	6
45	EUS-based Pancreatic Cancer Surveillance in <i>BRCA1/BRCA2/PALB2/ATM</i> Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 1033-1040.	0.7	5
46	Clinical and Functional Significance of TP53 Exon 4–Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
47	<i>PTEN</i> Loss and <i>BRCA1</i> Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	1.5	4
48	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncology Practice, 2021, 17, e1879-e1886.	1.4	2
49	Dietary influence on estrogens and cytokines in breast cancer. AIMS Molecular Science, 2017, 4, 252-270.	0.3	2
50	The differential diagnosis of a TP53 genetic testing result. Genetics in Medicine, 2018, 20, 806-808.	1.1	1
51	A Natural Language Processing–Assisted Extraction System for Gleason Scores: Development and Usability Study. JMIR Cancer, 2021, 7, e27970.	0.9	1
52	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. Current Breast Cancer Reports, 2012, 4, 199-206.	0.5	0
53	A classic presentation of an uncommon leukemia. American Journal of Hematology, 2013, 88, 431-432.	2.0	0
54	Reply. Gastroenterology, 2019, 157, 264-265.	0.6	0

#	Article	IF	CITATIONS
55	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		O
56	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e 1003302 .		0
57	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		O
58	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
59	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
60	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
61	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
62	Abstract 2237: Rates of intervention after initial versus subsequent whole-body MRI screening in Li-Fraumeni Syndrome. Cancer Research, 2022, 82, 2237-2237.	0.4	0